|With the world’s top biomedical talents and in-depth cooperation with numerous global scientific research institutions engaged in R&D of clinical new drugs and related products, Considerin has broken the monopoly of foreign patent drugs, realized independent R&D, and produced innovative drugs to enhance drug effectiveness, safety and reliability.|
In cooperation with Brown University, Considerin Group has developed clinical new drugs granted with global intellectual property rights, which are used for clinical treatment of brain tumors, liver cancer and kidney cancer brain metastases.
In cooperation with Purdue University, Considerin Group has developed clinical new drugs granted with global intellectual property rights, which are used for the clinical treatment of prostate cancer and pancreatic cancer.
Through joint development with Washington University, Considerin Group completed the coupling energy transfer design and the world’s first synthesis of double fluorescent nanoparticles. The nano-thermometer prepared by this nanoparticle can be directly calibrated by the peak value of two fluorescence peaks, and the peak ratio is linearly related to the temperature.